WX [WuXi PharmaTech (Cayman)] SC 13E3/A: EXECUTION VERSION U.S.$800,000,000 FACILITY AGREEMENT dated November 20,

[EXECUTION VERSION U.S.$800,000,000 FACILITY AGREEMENT dated November 20, 2015 for WUXI MERGER LIMITED arranged by PING AN BANK CO., LTD. ( DEVELOPMENT BANK CO., LTD. ( as Mandated Lead Arrangers with SHANGHAI PUDONG DEVELOPMENT BANK CO., LTD. ( as Facility Agent and PING AN BANK CO., LTD. ( as Security Agent CONTENTS CLAUSE PAGE SECTION 1 INTERPRETATION 1 1. Definitions] [EXECUTION VERSION U.S.$300,000,000 FACILITY AGREEMENT November 20, dated for GROUP & CLOUD LIMITED arranged by PING AN BANK CO., LTD. ( DEVELOPMENT BANK CO., LTD. ( as Mandated Lead Arrangers with SHANGHAI PUDONG DEVELOPMENT BANK CO., LTD. ( as Facility Agent and PING AN BANK CO., LTD. ( as Security Agent CONTENTS CLAUSE PAGE SECTION 1 INTERPRETATION 1 1. Definitions] [SECOND AMENDMENT TO THE AGREEMENT AND PLAN OF MERGER Amendment Parent Merger Sub Company This SECOND AMENDMENT TO THE AGREEMENT AND PLAN OF MERGER, dated as of November 20, 2015 (this “ Agreement WHEREAS, Parent, Merger Sub and the Company desire to enter into this Amendment, which shall amend the Agreement in accordance with the terms and conditions set forth] []

By | 2016-03-24T01:42:02+00:00 November 20th, 2015|Categories: Chinese Stocks, Webplus ver, WX|Tags: , , , , , |0 Comments
Read More

BSPM [Biostar Pharmaceuticals] NT 10-Q: (Original Filing)

[FORM 12b-25 NOTIFICATION OF LATE FILING CUSIP NUMBER: 090678 202 o o o (Check One): x o o For Period Ended: September 30, 2015 o o o o o For the Transition Period Ended: ____________________ Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. If the notification relates to a portion]

By | 2016-03-28T17:45:44+00:00 November 17th, 2015|Categories: BSPM, Chinese Stocks, SEC Original|Tags: , , , , , |0 Comments
Read More

BSPM [Biostar Pharmaceuticals] NT 10-Q: FORM 12b-25 NOTIFICATION OF LATE FILING CUSIP NUMBER:

[FORM 12b-25 NOTIFICATION OF LATE FILING CUSIP NUMBER: 090678 202 o o o (Check One): x o o For Period Ended: September 30, 2015 o o o o o For the Transition Period Ended: ____________________ Nothing in this form shall be construed to imply that the Commission has verified any information contained herein. If the notification relates to a portion]

By | 2016-03-28T17:47:11+00:00 November 17th, 2015|Categories: BSPM, Chinese Stocks, Webplus ver|Tags: , , , , , |0 Comments
Read More

CPHI [CHINA PHARMA] 10-Q: (Original Filing)

[FORM 10-Q (Mark One) x September 30, 2015 For the quarterly period ended o For the transition period from ____________ to ____________ CHINA PHARMA HOLDINGS, INC. Nevada 75-1564807 (State or other jurisdiction of (IRS Employer incorporation or organization) Identification No.) Second Floor, No. 17, Jinpan Road Haikou, Hainan Province, China 570216 +86- 898-6681-1730 (China) (Issuer's telephone number, including area code)] [CERTIFICATION OF OF THE SARBANES-OXLEY ACT OF 2002 I have reviewed this report on Form 10-Q of China Pharma Holdings, Inc.; Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were] [CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER OF THE SARBANES-OXLEY ACT OF 2002 I, Zhilin Li, certify that: 1. I have reviewed this report on Form 10-Q of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made,] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Dated: November 16, 2015 President and Chief Executive Officer (principal financial officer and principal accounting officer) EX-32.1 4 cphi10qex321093015.htm]

By | 2016-03-28T19:06:42+00:00 November 16th, 2015|Categories: Chinese Stocks, CPHI, SEC Original|Tags: , , , , , |0 Comments
Read More

CPHI [CHINA PHARMA] 10-Q: FORM 10-Q (Mark One) x September 30, 2015

[FORM 10-Q (Mark One) x September 30, 2015 For the quarterly period ended o For the transition period from ____________ to ____________ CHINA PHARMA HOLDINGS, INC. Nevada 75-1564807 (State or other jurisdiction of (IRS Employer incorporation or organization) Identification No.) Second Floor, No. 17, Jinpan Road Haikou, Hainan Province, China 570216 +86- 898-6681-1730 (China) (Issuer's telephone number, including area code)] [CERTIFICATION OF OF THE SARBANES-OXLEY ACT OF 2002 I have reviewed this report on Form 10-Q of China Pharma Holdings, Inc.; Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were] [CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER OF THE SARBANES-OXLEY ACT OF 2002 I, Zhilin Li, certify that: 1. I have reviewed this report on Form 10-Q of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made,] [18 U.S.C. SECTION 1350, SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. Dated: November 16, 2015 President and Chief Executive Officer (principal financial officer and principal accounting officer) EX-32.1 4 cphi10qex321093015.htm]

By | 2016-03-28T19:07:51+00:00 November 16th, 2015|Categories: Chinese Stocks, CPHI, Webplus ver|Tags: , , , , , |0 Comments
Read More

SVA [SINOVAC BIOTECH] 6-K: (Original Filing)

[Sinovac Reports Unaudited Third Quarter Financial Results -- Conference call scheduled for Thursday, November 12, 2015 at 8:00 AM ET -- BEIJING, November 11, 2015 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today its unaudited third quarter and nine month financial results for the period ended September 30, 2015. Third Quarter] []

By | 2016-03-16T06:10:31+00:00 November 13th, 2015|Categories: Chinese Stocks, SEC Original, SVA|Tags: , , , , , |0 Comments
Read More
Skip to toolbar